Objectives AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor …

Objective The fibroblast growth factor (FGF) family of signaling molecules has been
associated with chemoresistance and poor prognosis in a number of cancer types, including …

The recent identification of activating fibroblast growth factor receptor 2 (FGFR2) mutations
in endometrial cancer has generated an opportunity for a novel target-based therapy. Here …

Background Activating FGFR2 mutations are found in 10–16% of primary endometrial
cancers and provide an opportunity for targeted therapy. We assessed the safety and activity …

In the majority of cases, endometrial cancer is localized and highly curable through surgery
and adjuvant radiotherapy. However, for patients with advanced or metastatic disease …

Aberrant mutational activation of FGFR2 is associated with endometrial cancers (ECs).
AP24534 (ponatinib) currently undergoing clinical trials has been known to be an orally …

Purpose Activating mutations in FGFR2 have been identified as potential therapeutic targets
in endometrial cancer, typically occurring alongside genetic alterations that disrupt the …

Novel treatments that improve outcomes for patients with recurrent or metastatic endometrial
cancer (EC) remain an unmet need. Aberrant signaling by fibroblast growth factors (FGFs) …

Improved therapeutic approaches are needed for the treatment of recurrent and metastatic
endometrial cancer. Endometrial cancers display hyperactivation of the MAPK and PI3K …

Although molecularly targeted therapies have been effective in some cancer types, no
targeted therapy is approved for use in endometrial cancer. The recent identification of …